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Objective: Diabetic peripheral neuropathy is a major complication of diabetes mellitus (DM) and is the leading cause of
foot ulceration and lower extremity amputations (LEAs). The purpose of this systematic review is to evaluate current
evidence regarding the prognostic value of the Semmes Weinstein monofilament examination (SWME) in predicting foot
ulceration and LEA in patients with DM.
Methods:The MEDLINE/PubMed database was searched through November 2009 for articles pertaining to diabetic foot and
SWME with no language or publication date restrictions. Prognostic studies with original data assessing the predictive value
of SWME for foot ulceration or LEA in patients with DM were included in the selection. Data were systematically extracted
and analyzed by two independent investigators. Absolute risks and relative risks were determined for each study.
Results: Of the 863 studies identified, nine articles were relevant, involving 11,007 patients with DM. Six studies were
identified that assessed the prognostic value of SWME regarding diabetic foot ulceration. The relative risk for patients
with a positive SWME result versus those with a negative result ranged from 2.5 (95% confidence interval [CI], 2.0 to 3.2)
to 7.9 (95% CI, 4.4 to 14.3) in the identified studies with follow up between 1 and 4 years. Three of the studies assessed
the risk of LEA with a positive SWME result. The relative risk for LEA ranged from 1.7 (95% CI, 1.1 to 2.6) to 15.1 (95%
CI, 4.3 to 52.6) with follow-up between 1.5 and 3.3 years.
Conclusions: All nine studies found SWME to be a significant and independent predictor of future foot ulceration or likely of
future LEA as well in patients with DM. Therefore, SWME is an important evidence-based tool for predicting the prognosis
of patients with diabetic foot, thus enabling improved patient selection for early intervention and management. More research
should be conducted to elucidate the relationship between SWME and LEA. (J Vasc Surg 2011;53:220-6.)The World Health Organization (WHO) estimated
that more than 220million people worldwide have diabetes
mellitus (DM) and that the number will increase to 366
million by 2030.1 In the United States, 24 million people
had DM in 2008, an increase of more than 3 million in
approximately 2 years.2 Within this large diabetic popula-
tion, 30% of patients aged 40 years or older have impaired
sensation in the feet.2
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220Diabetic peripheral sensory neuropathy (DPN) in the
feet is one of the most frequent complications of DM.3 The
loss of sensory modalities results in the inability to sense
minor trauma, altered plantar pressure, and deformity of
the foot, subsequently leading to foot ulceration and lower
extremity amputations (LEAs). The lifetime incidence of
diabetic foot ulcers in patients with DM is approximately
15% and subsequently is responsible for more than 50% of
all nontraumatic LEAs.3
In the clinic, physicians often use the Semmes Wein-
stein monofilament examination (SWME) as a noninvasive,
low-cost, rapid, and easy-to-apply test to identify patients at
high risk for ulceration or amputation. The monofilaments
are applied to test sites on each foot perpendicularly until
they bend for about one second. If patients fail to sense the
monofilament after it bends, the test site is considered to be
insensate. The general consensus regarding the definition
of loss of protective sensation involves the inability to
sense the 5.07/10 g Semmes Weinstein monofilament.
The buckling force of this monofilament, the force felt
by the patient when the monofilament bends, is 10
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gauge, which is 5.07 for this monofilament.4 The methods
for performing the SWME vary greatly, with differences in
the number of sites and the threshold for defining the loss
of sensation. Recent meta-analysis of our group has estab-
lished that a three-site SWME test involving the plantar
aspects of the great toe, the third, and the fifth metatarsals
maximizes the sensitivity and specificity of the test in diag-
nosing DPN.5 However, evidence about the predictive
value of SWME with regards to foot ulceration and LEA
during follow-up is lacking.
A critical appraisal of the current evidence in literature
was performed by means of a systematic review to provide
more insight into the prognostic value of SWME in pre-
dicting foot ulceration and LEA during follow-up in pa-
tients with DM.
METHODS
Data selection. The search sequence was performed in
the Back66 file of the Medline Database via MEDLINE/
PubMed on November 15, 2009, resulting in 863 articles.
The search strategy is shown in Appendix I (online only).
The initial search was purposefully made very broad to
ensure that no relevant articles were missed. The search
resulted in 863 studies. No language or publication date
restrictions were applied. All titles and abstracts of these
863 studies were reviewed for relevance by at least two
independent investigators. In this process, 145 studies were
selected based on the following criteria: (1) includes use of
Semmes Weinstein monofilament; (2) pertains to diabetic
neuropathy in the feet; and (3) conducts original research.
Full texts of all these 145 studies were obtained and read by
two independent investigators. Also, the references of rel-
evant studies were searched for any other relevant articles.
Subsequently, a final selection was made on the basis of the
following inclusion criteria: (1) the objective was to quan-
tify the predictive value of SWME, and (2) data on ulcer-
ation and LEA during follow-up were described for pa-
tients with negative and positive SWME results. Ultimately,
nine studies were identified that fit the criteria for relevance,
which are shown in Fig 1. The validity of the data in the
selected articles was determined according to the Oxford
Center For Evidence-Based Medicine’s levels of evidence.6
Statistical analysis. Data regarding the number of
patients with a positive SWME result, number of patients
with a negative SWME result, length of follow-up in years,
number of patients with a negative SWME result and foot
ulceration during follow-up, number of patients with a
positive SWME result and foot ulceration during follow-
up, number of patients with a negative SWME result and
LEA during follow-up, and number of patients with a
positive SWME result and LEA during follow-up were
extracted from each of the articles. For each study, the
absolute risks of the outcome for patients with positive
SWME results and for those with negative SWME results
were calculated for the presented follow-up period. The
risk difference was defined as the difference between the
absolute risk of the outcome for patients with positiveSWME results minus the absolute risk for patients with
negative SWME results and calculated for each of the
articles. Lastly, the relative risks of the outcome for
patients with positive SWME results versus those with
negative results were calculated. Calculations were done
from the original crude data presented in the articles to
determine any missing prognostic values as well as 95%
confidence interval (CI) for the risk differences and
relative risks.7
RESULTS
Nine articles matched all of the inclusion criteria and
were selected.8-16 These nine studies included a total of
11,007 patients with DM. All selected studies met the
Oxford Center for Evidence-Based Medicine’s levels of
evidence of 2b or higher.6 All nine studies were prospective
cohort studies assessing and associating the SWME result
with the risk of foot ulceration or LEA during follow-up.
Length of follow-up, methodology of application of the
SWME, and precise definition of study outcome varied
between the selected studies.
Seven studies associated the SWME result with the risk
of foot ulceration.8-14 Appendix II (online only) lists these
studies with their specific study domain, method of SWME
application, definition of the study outcome, and the asso-
ciated prognostic values. All seven studies showed that a
positive SWME result was a significant and independent
predictor of foot ulceration during follow-up. Absolute risk
of ulceration with positive SWME results and that with
negative SWME results are graphed in Fig 2. With negative
SWME results, the absolute risk of developing ulcers
ranged between 2.5% (95% CI, 2.1 to 3.0) and 10.7% (95%
CI, 8.8 to 13.1). However, with positive SWME results,
the absolute risk of ulceration was higher and ranged from
12.4% (95% CI, 0.7 to 14.3) to 38.6% (95% CI, 28.1 to
50.3). The risk difference of foot ulceration for those with
Fig 1. Summary of the article selection process.positive SWME results compared with those with negative
hese t
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33.7% (95% CI, 22.7 to 45.6). The relative risks of foot
ulceration for patients with positive SWME results com-
Fig 2. The absolute risk for a positive SWME result, the
of ulceration in patients with diabetes mellitus as indicated
length of the studies. *The methodology of SWME in tpared with those with negative SWME results ranged from2.5 (95% CI, 2.0 to 3.2) to 7.9 (95% CI, 4.4 to 14.3), and
are also shown graphically in Fig 2.
Three studies assessed the risk of LEA.11,15-16 The
lute risk for a negative SWME result, and the relative risk
ppendix II (online only) are shown against the follow-up
wo studies involved testing at less than 3 sites.abso
in Astudies, along with their study domain, testing methods,
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(online only). It was not possible to distinguish the predic-
tive value for major amputations from that for minor am-
putations. The prognostic value of SWME results on the
risk of LEA widely varied between these studies. Although
the extent of the effect differed, the direction was the same:
all three studies found a positive SWME result to be a
significant and independent predictor of future LEA. Ab-
solute risk of LEA with positive SWME results and with
negative SWME results are graphed in Fig 3. With negative
SWME results, the absolute risk of LEA ranged between
1.0% (95% CI, 0.4 to 3.0) and 21.4% (95% CI, 14.9 to
29.6). With positive SWME results, the absolute risk of
LEA was between 6.4% (95% CI, 4.4 to 9.3) and 35.3%
(95% CI, 26.0 to 45.9). The risk difference of LEA for
those with positive SWME results compared with those
with negative SWME results ranged from 5.1% (95% CI,
2.5 to 8.1) to 14.7% (95% CI, 7.7 to 25.0). The relative
risks of LEA for patients with a positive SWME result
compared with patients with a negative SWME result are
also shown in Fig 3 and ranged between 1.7 (95%CI, 1.1 to
2.6) and 15.1 (95% CI, 4.3 to 52.6).
DISCUSSION
A noninvasive semi-quantitative examination should be
done regularly by SWME as per recommendations of the
Center for Medicare and Medicaid Services, the Interna-
tional Diabetes Federation, and the World Health Organi-
zation.4,17-18 Based on literature on the methodology of
SWME, we previously determined that the optimal method
to use the 5.07/10 g monofilament is to test the plantar
aspects of the great toe, third, and fifth metatarsal heads
with the threshold of the test set at one insensate site.5 This
study presents a systematic review of current literature and
provided more insight into the prognostic value of SWME
in predicting foot ulceration and LEA during follow-up in
patients with DM. Because the studies differed in follow-up
length, method of SWME, and definitions of outcome,
data were not combined from multiple studies. Therefore,
all prognostic values presented were derived from individ-
ual studies. Absolute risk presented in this study represents
the chance of ulceration or LEA for a patient with diabetes.
The risk difference represents the amount by which the
chance of ulceration or LEA increases when the patient has
lost protective sensation as assessed by 5.07/10 g SWME.
Lastly, relative risk reports how many times more likely a
patient with positive SWME results is going to develop
ulceration or LEA than a patient with negative SWME
results. Based on these three prognostic variables, it is clear
that SWME is correlated with an increased risk of ulceration
as well as LEA. It has significant predictive power as a
screening tool for patients with diabetes in clinical settings.
All seven studies assessing the risk of foot ulceration
concluded that a positive 5.07/10 g SWME result is asso-
ciated with an increased risk of foot ulceration.8-14 By
finding patients with DM positive for SWME, their chance
of developing a foot ulcer increases roughly by 10% to 20%.
The relative risk of patients with a positive SWME resultcompared with those with a negative SWME result ranged
from 2.5 (95% CI, 2.0 to 3.2) to 4.9 (95% CI, 2.5 to 9.6).
Based on these data, it can be seen that by having positive
SWME results, the risk of foot ulceration is approximately
2.5 to 5 times higher than in patients with a negative
SWME result. The data on the risk of ulceration analysis
revealed one study by Rith-Najarian et al in which both the
increase in absolute risk as well as the relative risk were
considerably higher than these risk values from other stud-
ies.11 The subjects in this study included patients with foot
deformities present at baseline and therefore with relatively
advanced disease status. This explains the high risks pre-
sented in this study.
Positive 5.07/10 g SWME results were also found to
be an indicator of increased risk of LEA in the three selected
studies.11,15-16 By detecting a positive SWME result in
patients with diabetes, they have roughly a 5% to 15%
increased risk of requiring a LEA during follow-up. Addi-
tionally, because relative risk ranged from 1.7 (95% CI, 1.1
to 2.6) to 15.1 (95% CI, 4.3 to 52.6), it is shown that
patients with positive SWME results are roughly 1.5 to 15
times as likely to require LEA during subsequent follow-up.
The risks of LEA and the association between the SWME
test results and the risk of LEA widely varied between the
studies. On analysis, it was seen that the above described
situation in the study by Rith-Najarian et al most likely also
affected the LEA data in the same way.11 Also, the study by
Nather et al took place in Singapore with 72.8% of the
patients classified as having poor control of diabetes.15 In
addition, 27.7% of the patients in the study already had foot
ulcers at baseline. It is obvious that the domain of this study
greatly increased the absolute risk of LEA in patients both
positive and negative for SWME. Because of this high
absolute risk, relative risk became very small in this study.
The confounding variables introduced in these two studies
generated large variations in the LEA risk data. While all
three studies pointed in the direction that a positive SWME
result is a significant predictor of LEA, more randomized
follow-up trials need to be performed to ascertain the
association between SWME and LEA.
There were several areas of variation in the nine studies
presented. Because of the substantial heterogeneity be-
tween studies, meta-analysis was not appropriate for statis-
tical reasons. Even though the follow-up duration varied
from 1 year to 4 years, no association between the length of
follow-up and risk was observed. Also, the differences in the
percentage of patients with history of ulceration or history
of amputation across studies did not have any clear associ-
ations with the differences among the predictive values of
SWME across studies. The differences in predictive values
are likely to be caused by differences in disease status of the
different study populations. The methodology of SWME
also varied greatly among studies and most likely had an
effect on the risk data for ulceration. Because SWME needs
at least three sites on the plantar aspect of the foot to be
tested to reach its maximum sensitivity, Pham et al and
McGill et al may have grouped patients with DPN incor-
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lower extremity amputation in patientswith diabetesmellitus as indicated inAppendix III (online only) are shown against the
follow-up length of the studies.
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patients with impaired protective sensation.5,10,14
The definition of ulceration slightly varied across stud-
ies. However, regardless of the specificity of each definition,
all studies defined ulcers by a full thickness skin defect on
the foot studies. With regards to LEA, unfortunately it was
not possible to make distinctions between minor and major
amputations when calculating the prognostic values from
the selected studies. For this reason, any amputations,
including below-knee amputations, above-knee amputa-
tions, ray amputation, or disarticulation, were all classified
as LEA. Because of the large variation in the results and the
lack of distinction between types of amputations, more
research needs to be conducted to confirm the association
between positive SWME results and increased risk for LEA.
Future research should include prospective randomized
follow-up trials that utilize the three-site method and assess
the risk for various types of amputations. The data from this
study show that it is likely positive SWME results lead to
higher risks of any kind of LEA, but this needs further
confirmation through future research.
Ultimately, this analysis has shown that SWME is a
significant predictor of the risk of ulceration and likely LEA
as well during subsequent follow-up in patients with DM.
SWME can be an inexpensive, accurate, and painless way
for primary and specialty care physicians to identify high-
risk patients during a physical examination. Currently,
Medicare only reimburses SWME as a part of the foot
examination for the loss of protective sensation, for which
Medicare reimburses $44.72.19-20 SWME is not reim-
bursed as a separate service, often hindering accessibility to
the test. The cost of disposable monofilaments is merely
around $0.45 each when purchased from an independent
supplier.4 Once loss of protective sensation at any site is
identified by SWME, patients should be provided with an
intensive foot care education program in addition to appro-
priate therapeutic footwear.18 Medicare currently covers
one pair of therapeutic shoes per year if there are docu-
mented signs of nerve damage with calluses.21 It should be
emphasized, however, that foot examinations are adjuncts
and cannot replace early detection of diabetes partnered
with strict glycemic control and close monitoring of hemo-
globin A1c.22 Using SWME as a screening test is not
necessary for patients with overt clinical evidence of DPN,
such as ulceration. However, applying SWME on the con-
tralateral extremity that does not display overt symptoms
may help assess the degree of DPN as well as the risk for
ulceration and amputation in that extremity.
This systematic review serves as a comprehensive ap-
praisal of all the studies performed on the prognostic prop-
erties of SWME. Based on the current literature, SWME is
themost practical test to perform in the primary care setting
to identify patients with DM that are at increased risk of
ulceration and likely LEA as well. If the studies had fol-
lowed the optimal method using three sites,5 the predictive
value of SWME could even be higher than those presented
in this study. Based on the results of this review, a future
large-scale prospective cohort study utilizing the three-sitemethod would be able to even more accurately and pre-
cisely characterize the predictive value of SWME. One
possible deficiency is that this review did not account for
publication bias. However, for the purposes of this review,
the main goal of assessing whether SWME can identify
patients at increased risk to warrant special precautions was
accomplished. Further experimentation is needed to more
concretely establish the correlation between positive
SWME results and different kinds of LEA. When assessing
the risk of LEA, ulceration needs to be taken into account
since it acts as a confounding variable that greatly increases
risk. Performed correctly, SWME is a significant and impor-
tant predictor of future foot ulceration andmost likely LEA
as well, improving clinical outcomes for patients with dia-
betes.
CONCLUSIONS
A positive SWME result is a significant predictor of
future ulceration and likely LEA as well in patients with
DM. SWME is an inexpensive, accurate, reliable, and prac-
tical modality for physicians to identify patients that are at
increased risk for developing ulcers or requiring LEAs. If
diabetic patients have positive SWME results, their chances
of ulceration increase with 10% to 20%, corresponding with
a 2.5- to 5-times higher risk than patients with normal
sensation as determined by SWME. Additionally, the risks
of LEA increase with 5% to 15%, which corresponds with a
1.5- to 15-times higher risk for patients with DM with
positive SWME results compared with those with negative
SWME results. However, this conclusion regarding LEA
requires further experimental confirmation, as only three
prospective follow-up studies currently exist on this matter.
For the above reasons, SWME is an important evidence-
based tool for determining which patients are at increased
risk of complications during follow-up, leading to im-
proved patient selection for early intervention and manage-
ment. Ultimately, screening with SWME may lead to im-
proved clinical outcomes for patients with diabetic foot.
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Diabetes Neuro
Title/Abstract MeSH terms Title/Abstract
sorbitol “Diabetes Mellitus” AND neuropath
“glucose
intolerance”
“Diabetes Mellitus,
Type 2”
amyotroph
diabet “Diabetes Mellitus,
Type 1”
neuralg
hyperglyc “Diabetes
Complications”
polyneuropath
“Diabetes
Complications”
mononeuropath
“Glucose
Intolerance”
pals
“Sorbitol” ischemi
angiopath
microvasc
(endotheli AND
hyperplas)
atherosclero
(periph AND vasc)
Foot
Feet
Plantar
Callus
ulcer
Cellulitis
Osteomyelitis
streptococc
staphylococc
Aureus
The search terms in the above three categories were connected by AND. All
were all connected by OR. The asterisk () was used to truncate search termic value of Semmes Weinstein monofilament examination
pathy SWME
MeSH terms Title/Abstract MeSH terms
“Diabetic
Neuropathies”
AND frey “Microfilaments”
“Vascular Diseases” semmes “Sensory
Thresholds”
“Peripheral
Vascular
Diseases”
Weinstein
“Foot diseases” filamen
“Foot Ulcer” monofilam
“Diabetic Foot” microfilam
“Diabetic
Angiopathies”
aesthesiometer
“touch assessment”
esthesiometer
“threshold detection”
“sensory testing”
“mechanical
sensitivity”
“touch test”
“cutaneous touch
pressure”
terms within each of the three categories, title/abstract terms, and MeSH Terms,
he follow-up length for the study. The last four columns present the absolute risk
rence, and the relative risk of ulceration.
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Study Domain SWM
Litzelman et al8 352 DM 1/3 s
Abbott et al (ref 9) 6613 DM, 4% HOU, 1% HOA 1/3 s
Pham et al10 248 DM, 35% HOU 1/1 s
Rith-Najarian et al11 358 DM, 13% HOU 1/8 s
Boyko et al12 1285 DM, 25% HOU, 5%
HOA
1/9 s
Boyko et al13 701 DM, 33% HOU, 7% HOA 1/9 s
McGill et al14 472 DM, 10% HOU, 3% HOA 1/2 s
CI, Confidence interval; DM, diabetes mellitus; HOA, history of ampu
examination.
The absolute risk, risk difference, and relative risk of ulceration for each study
specific descriptions of the study populations including the percent of patie
information regarding the methodology of SWME in the identified articles.
tested. Ex: 1/2 sites on each foot means the inability to detect one site out o
column shows the definition of the outcome while the fifth column shows t
for a positive SWME result, that for a negative SWME results, the risk diffeE methodology Outcome (Definition of Ulceration)
ites on both feet Foot ulcer Seattle Wound Class 1.2
ites on both feet Full thickness skin defect Wagner Stage 1
ites on both feet Foot ulceration
ites on both feet Full thickness skin defect on plantar aspect of foot
ites on both feet Full thickness skin defect requiring 14
days to heal
ites on both feet Full thickness skin defect requiring 14
days to heal
ites on both feet Foot ulceration
tation; HOU, history of ulceration; SWME, Semmes Weinstein monofilament
were calculated. The first column shows the studies, and the second column shows
nts with a history of ulceration or amputation. The third column shows detailed
The fractions in this column show the threshold for diagnosis/the number of sites
f two sites on each foot was considered to be a positive SWME result. The fourth
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Follow up
duration
(Years)
Absolute risk of
outcome for positive
SWME (95% CI)
Absolute risk
for negative
(95% C
1 15.3% (10.4 to 22.0) 3.5% (1.7
2 12.4% (10.7 to 14.3) 2.5% (2.1
2.5 24.6% (20.4 to 29.4) 6.3% (3.3
2.7 38.6% (28.1 to 50.3) 4.9% (2.9
3.4 26.9% (23.2 to 31.0) 10.7% (8.8
3.7 17.7% (14.9 to 20.9) 6.0% (4.6
4 18.8% (11.7 to 28.7) 3.8% (2.3of outcome
SWME
I)
Risk difference
(95% CI)
Relative risk
(95% CI)
to 7.0) 11.9% (5.8 to 18.7) 4.4 (2.0 to 10.0)
to 3.0) 9.9% (8.1 to 11.8) 4.8 (3.8 to 6.1)
to 11.5) 18.4% (11.7 to 24.0) 3.9 (2.0 to 7.6)
to 8.0) 33.7% (22.7 to 45.6) 7.9 (4.4 to 14.3)
to 13.1) 16.2% (11.8 to 20.8) 2.5 (2.0 to 3.2)
to 7.8) 11.7% (8.4 to 15.2) 3.4 (2.5 to 4.6)
to 6.2) 14.9% (7.5 to 24.9) 4.9 (2.5 to 9.6)
ation for each study were calculated. Columns match the categories in Appendix
JOURNAL OF VASCULAR SURGERY
January 2011226.e4 Feng et alAppendix III (online only). Risk of lower extremity amp
Study Domain
Nather et al15 202 DM, 27% HOU
Rith-Najarian et al11 358 DM, 13% HOU
Adler et al16 776 DM, 19% HOU, 7% HOA
CI,Confidence interval;DM, diabetes mellitus;HOA, history of amputation
Weinstein monofilament examination.
The absolute risk, risk difference, and relative risk of lower extremity amput
II (online only).utation
SWME methodology Outcome
Follow up
duration (Years)
N/A LEA 1.5
1/8 sites on both feet LEA 2.7
1/9 sites on both feet LEA 3.3
;HOU, history of ulceration; LEA, lower extremity amputations; SWME, Semmes
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Absolute risk of outcome
for positive SWME (95% CI)
Absolute risk of outcom
for negative SWME (95%
35.3% (26.0 to 45.9) 21.4% (14.9 to 29.6
15.7% (9.0 to 26.0) 1.0% (0.4 to 3.0)
6.4% (4.4 to 9.3) 1.3% (0.6 to 3.0)e
CI)
Risk difference
(95% CI)
Relative risk
(95% CI)
) 13.9% (1.5 to 26.3) 1.7 (1.1 to 2.6)
14.7% (7.7 to 25.0) 15.1 (4.3 to 52.6)
5.1% (2.5 to 8.1) 4.9 (1.9 to 12.8)
